Oncolytics Biotech issued 25th U.S. patent

Oncolytics has announced that it has been granted U.S. Patent 7,306,902 entitled "Oncolytic Viruses as Phenotyping Agents for Neoplasms.

" The claims describe methods of diagnosing cancers with unknown phenotypes by using oncolytic viruses that selectively replicate in cancer cells with known phenotypes.

"Oncolytic viruses are selective for certain mutations in cancer cells," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "By using these viruses in tumour samples, we may be able to more accurately diagnose the various cancer phenotypes, ultimately leading to a more individualized approach to cancer treatment."